文献库，生知库 | 链接生命科学的每一步

日期影响因子

The Role of Lifestyle Modifications in Preventing and Managing Systemic Hypertension: Current Guidelines and Future Directions

生活方式干预在预防和控制系统性高血压中的作用：当前指南和未来方向

doi:10.1007/s40271-023-00648-5

Mease, Catherine; Fermaglich, Lewis J; Jackler, Karen; Shermer, Shawn; Miller, Kathleen L; Elmakki, Erwa

发表日期：2025

文献求助收藏

Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development

对FDA罕见儿科疾病优先审评券计划实施前十年的分析：认定、疾病和药物研发

期刊:Orphanet Journal of Rare Diseases

影响因子:3.5

doi:10.1186/s13023-024-03097-x

Mease, Catherine; Miller, Kathleen L; Fermaglich, Lewis J; Best, Jeanine; Liu, Gumei; Torjusen, Erika

发表日期：2024

文献求助收藏

Correction to: Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development

更正：FDA罕见儿科疾病优先审评券计划前十年分析：认定、疾病和药物研发

期刊:Orphanet Journal of Rare Diseases

影响因子:3.5

doi:10.1186/s13023-024-03136-7

Mease, Catherine; Miller, Kathleen L; Fermaglich, Lewis J; Best, Jeanine; Liu, Gumei; Torjusen, Erika

发表日期：2024

文献求助收藏

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act

一项对《孤儿药法案》实施四十年来孤儿药认定和批准所针对的罕见疾病和病症的全面研究

期刊:Orphanet Journal of Rare Diseases

影响因子:3.5

doi:10.1186/s13023-023-02790-7

Fermaglich, Lewis J; Miller, Kathleen L

发表日期：2023

文献求助收藏

Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies

获得FDA孤儿药资格认定的药物和生物制剂：最常被认定的产品及其重新定位策略分析

期刊:Expert Opinion on Orphan Drugs

影响因子:0.8

doi:10.1080/21678707.2021.2047021

Miller, Kathleen L; Kraft, Selma; Ipe, Abraham; Fermaglich, Lewis

发表日期：2022

文献求助收藏

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases

利用美国食品药品监督管理局（FDA）过去四十年的孤儿药认定数据来描述罕见病药物研发的趋势：罕见肿瘤、神经系统疾病和儿童期发病疾病的药物研发均呈现显著增长。

期刊:Orphanet Journal of Rare Diseases

影响因子:3.5

doi:10.1186/s13023-021-01901-6

Miller, Kathleen L; Fermaglich, Lewis J; Maynard, Janet

发表日期：2021

文献求助收藏

Gout induced by L-dopa and decarboxylase inhibitors

左旋多巴和脱羧酶抑制剂诱发的痛风

期刊:Postgraduate Medical Journal

影响因子:2.7

doi:10.1136/pgmj.52.606.232

Calne, D B; Fermaglich, J

发表日期：1976

文献求助收藏